What the FDA labels say about taking them together
Glimepiride and pramlintide
Glimepiride's FDA label of May 12, 2025 names pramlintide in its drug interactions section; pramlintide's label does not name glimepiride itself but warns about its class (Sulfonylureas). The glimepiride label: “… susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene …”
Check it at the source: the glimepiride FDA label on DailyMed (effective May 12, 2025, Micro Labs Limited); the pramlintide FDA label on DailyMed (effective December 18, 2019, AstraZeneca Pharmaceuticals LP).
What does the glimepiride label say about pramlintide?
Glimepiride label, drug interactionsThe following are examples of medications that may increase the glucose-lowering effect of sulfonylureas including glimepiride, increasing the susceptibility to and/or intensity of hypoglycemia: oral anti-diabetic medications, pramlintide acetate, insulin, angiotensin converting enzyme (ACE) inhibitors, H 2 receptor antagonists, fibrates, propoxyphene, pentoxifylline, somatostatin analogs, anabolic steroids and androgens, cyclophosphamide, phenyramidol, guanethidine, fluconazole, sulfinpyrazone, tetracyclines, clarithromycin, disopyramide, quinolones, and those drugs that are highly protein-bound, such as fluoxetine, nonsteroidal anti-inflammatory drugs, salicylates, sulfonamides …
Source: FDA drug label (Glimepiride), Micro Labs Limited, effective May 12, 2025 (SPL set 60e9397e-83b9-489e-9683-6f87e458bbaa), via openFDA; the full label on DailyMed
What does the pramlintide label say about glimepiride?
Pramlintide's label does not name glimepiride itself; it warns about its class (Sulfonylureas):
Pramlintide label, warnings and precautionsThe addition of any anti-diabetic medication, such as SYMLIN, to an existing regimen of one or more anti-diabetic medications (e.g., sulfonylurea), or other medications that can increase the risk of hypoglycemia may necessitate further insulin dose adjustments and particularly close monitoring of blood glucose.
Source: FDA drug label (SymlinPen), AstraZeneca Pharmaceuticals LP, effective December 18, 2019 (SPL set 4aea30ff-eb0d-45c1-b114-3127966328ff), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glimepiride | Pramlintide | |
|---|---|---|
| Labeled for | Type 2 diabetes | Type 2 diabetes, Type 1 diabetes |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.0507 per tablet 4 mg tablet | n/a |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once